Skip to content
DataLookout
Menu

PALISADES-1NCT04989803

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

StatusActive, Not Recruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 52 versions: 30 with changes below, 20 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria shortened, about 10 words
    • Enrollment closed, study ongoing
    • Study sites: 34 to 36
    • Secondary endpoints: details revised at 14 of 22 entries
  2. Notable Eligibility criteria expanded, about 15 words
    • Primary endpoints: details revised at 1 of 3 entries
    • Trial sites expanded: 28 → 34 locations
    • Secondary endpoints: details revised at 16 of 22 entries
  3. Minor Study sites: 26 to 28v50
  4. Minor Trial sites expanded: 21 → 26 locationsv49
  5. Minor Trial sites expanded: 18 → 21 locationsv48
  6. Notable Primary and study completion pushed from Oct 2027 to Feb 2030
    • Eligibility criteria expanded, about 9 words
    • Trial sites expanded: 14 → 18 locations
    • Secondary endpoints: 24 to 22
    v47
  7. Notable Phase: Phase 1 to Phase 1/2v46 Show 5 more changesShow less
    • Enrollment target: 114 to 247
    • Eligibility criteria expanded, about 27 words
    • Primary endpoints: 2 to 3
    • Secondary endpoints: 16 to 24
    • Study arms: 2 to 3
  8. Minor Primary and study completion dates: May 2027 to Oct 2027v44
  9. Minor Site details revised at 1 of 14 sitesv43
  10. Notable Primary and study completion dates: Jul 2026 to May 2027v42
  11. Minor Study sites: 12 to 14v41
  12. Minor Study sites: 10 to 12v39
  13. Minor Study sites: 9 to 10v34
  14. Minor Site details revised at 1 of 9 sitesv33
  15. Notable Primary completion date: Jul 2025 to Jul 2026
    • Study completion date: Jan 2027 to Jul 2026
    v32
  16. Notable Primary completion date: Apr 2024 to Jul 2025
    • Study completion date: Jan 2041 to Jan 2027
    v31
  17. Minor Study sites: 8 to 9v30
  18. Minor Study sites: 6 to 8v26
  19. Notable Eligibility criteria expanded, about 6 wordsv25 Show 6 more changesShow less
    • Enrollment target: 80 to 114
    • Study sites: 5 to 6
    • Interventions: Cyclophosphamide (Drug), Fludarabine (Drug), KITE-363 (Biological) to Cyclophosphamide (Drug), Fludarabine (Drug), KITE-363 (Biological), KITE-753 (Biological)
    • Study arms: 1 to 2
    • Study description shortened, about 4 words
    • Study title expanded, about 2 words
  20. Minor Study sites: 4 to 5v24
  21. Study Identification, Study Status, Study Descriptionv23
  22. Minor Study sites: 3 to 4v22
  23. Notable Eligibility criteria expanded, about 12 wordsv21
  24. Minor Site details revised at 1 of 3 sitesv16
  25. Minor Study sites: 2 to 3
    • Primary completion date: Feb 2024 to Apr 2024
    v11
  26. Notable Primary completion date: Jan 2026 to Feb 2024v10
  27. Minor Study sites: 1 to 2v8
  28. Notable Eligibility criteria shortened, about 30 words
    • Start date changed from estimate of Nov 2021 to Oct 27, 2021
    v6
  29. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Oct 2021 to Nov 2021
    • Study site revised
    v5
  30. Minor Study sites: 0 to 1v3
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Phase 1a: Percentage of Participants Experiencing Adverse Events Defined as Dose-limiting Toxicities (DLTs) After the Infusion of KITE-363 or KITE-753
Timeframe: Up to 28 days
Phase 1b: Objective Response Rate (ORR) for KITE-363 and KITE-753 as per investigator's assessment.
Timeframe: Up to 24 months
Phase 2: ORR as per central assessment for KITE-753
Timeframe: Up to 36 months

Secondary (22)

Phase 1a/b: Percentage of Participants Experiencing Adverse Events (AEs) After the Infusion of KITE-363 and KITE-753
Phase 1a/b: Percentage of Participants Experiencing Serious AEs (SAEs) After the Infusion of KITE-363 and KITE-753
Phase 1a/b: Time To Next Treatment (TTNT) for KITE-363 and KITE-753
Phase 1a/b: Complete Response (CR) Rate for KITE-363 and KITE-753
Phase 1a/b: Duration of Response (DOR) for KITE-363 and KITE-753
Show 17 moreShow less
Phase 1a/b: Progression-Free Survival (PFS) for KITE-363 and KITE-753
Phase 1a/b: Overall Survival (OS) for KITE-363 and KITE-753
Phase 1a/b: Percentage of Participants who Develop Antibodies to KITE-363 and KITE-753 Chimeric Antigen Receptor (CAR) T Cells
Phase 1a/b: Levels of KITE-363 and KITE-753 CAR T Cells
Phase 1a/b: Peak Serum Levels of Key Analytes Homeostatic/Proliferative Cytokines: Interleukin (IL)-2, IL-7, and IL-15
Phase 1a/b: Peak Serum Levels of Key Analytes Inflammatory/Immune Modulating Cytokines: IFN-γ, IL-6, IL-10, IL-17, IL-1RA, Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), and Tumor Necrosis Factor-Alpha (TNF-α)
Phase 1a/b: Peak Serum Levels of Key Analytes Correlates of Acute Phase Response: C-Reactive Protein (CRP)
Phase 1a/b: Peak Serum Levels of Key Analytes Correlates of Acute Phase Response: Ferritin
Phase 1a/b: Peak Serum Levels of Key Analytes Correlates of Acute Phase Response: Soluble IL-2 Receptor Alpha (Sil-2Rα)
Phase 1a/b: Peak Serum Levels of Key Analytes Chemokines: IL-8, C-X-C Motif Chemokine Ligand-10 (CXCL-10), and Monocyte Chemotactic Protein-1 (MCP-1)
Phase 1a/b: Peak Serum Levels of Key Analytes Immune-Effector Molecules: Perforin, Granzyme A, and Granzyme B
Phase 2: CR rate for KITE-753
Phase 2: DOR for KITE-753
Phase 2: PFS for KITE-753
Phase 2: OS for KITE-753
Phase 2: Percentage of Participants Experiencing Adverse Events (AEs) After the Infusion of KITE-753
Phase 2: Percentage of Participants Experiencing Serious AEs (SAEs) After the Infusion of KITE-753

Arms and interventions

Phase 1 a/b: KITE-363Experimental

Phase 1a (Dose escalation): Participants with r/r large B-cell lymphoma will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single target starting dose of KITE-363 chimeric antigen receptor (CAR) transduced autologous T cells. Based on dose limiting toxicities (DLTs) observed in the first cohort, additional participants will be enrolled and administered escalating dose of KITE-363. Phase 1b (Dose expansion): After completion of dose escalation, additional participants with r/r B-cell lymphoma across different disease indications will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single dose of KITE-363 at 1 or more dose-level deemed to be tolerable. \[Recruitment completed for this arm\]

Phase 1 a/b: KITE-753Experimental

Phase 1a (Dose escalation): Participants with r/r large B-cell lymphoma will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single target starting dose of KITE-753 chimeric antigen receptor (CAR) transduced autologous T cells. Based on dose limiting toxicities (DLTs) observed in the first cohort, additional participants will be enrolled and administered escalating dose of KITE-753. Phase 1b (Dose expansion): After completion of dose escalation, additional participants with r/r B-cell lymphoma across different disease indications will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single dose of KITE-753 at 1 or more dose-level deemed to be tolerable. \[Recruitment open for frontline LBCL and r/r MCL for this arm\]

Phase 2: KITE-753Experimental

Participants with r/r large B-cell lymphoma who have received at least 2 prior lines of systemic therapy will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single target starting dose of KITE-753 chimeric antigen receptor (CAR) transduced autologous T cells /kg intravenously (IV).

Drugs: Cyclophosphamide, Fludarabine

Biologicals: KITE-363, KITE-753

Sites

36 sites in 6 countries

United States 21, Australia 6, Canada 5, Netherlands 2, Germany 1, United Kingdom 1